Table 3 Multivariate logistic regression analysis to identify associated factors with baseline and monitoring examinations.

Age (years)

0.997 (0.995–0.999)

0.005

0.989 (0.986–0.993)

 < 0.001

Sex

 Male

1 (reference)

1 (reference)

 < 0.001

 Female

1.314 (1.209–1.428)

1.346 (1.176–1.541)

Residence

 Metropolitan area/large cities

1 (reference)

0.004

1 (reference)

 < 0.001

 Small cities/rural

0.912 (0.857–0.971)

0.657 (0.601–0.718)

Medical specialties prescribing HCQ

 Rheumatology

1.074 (0.961–1.200)

 < 0.001

1.185 (1.006–1.396)

 < 0.001

 Dermatology

1.522(1.281–1.807)

0.994 (0.727–1.358)

 Internal medicine other than rheumatology

0.870 (0.766–0.988)

0.845 (0.707–1.011)

 Others

1 (reference)

1 (reference)

Hospitals of prescription

 Primary

1 (reference)

 < 0.001

1 (reference)

 < 0.001

 Referral centers

1.563 (1.407–1.736)

2.312 (1.975–2.708)

Indications for HCQ use

 SLE

1.713 (1.561–1.881)

 < 0.001

1.349 (1.190–1.529)

 < 0.001

 RA

0.689 (0.634–0.748)

0.570 (0.508–0.641)

 Others

1 (reference)

1 (reference)

Mean duration (month)

1.000 (0.998–1.002)

0.892

1.017 (1.015–1.019)

 < 0.001

Mean daily dose (mg)

0.998 (0.998–0.999)

 < 0.001

0.998 (0.998–0.999)

 < 0.001